CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Enbrel (etanercept) — Coverage Criteria

Defines prior authorization, documentation, prescriber specialty, and coverage criteria for Enbrel (etanercept) for FDA-approved and selected compendial indications for Neighborhood Health Plan of Rhode Island members.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyEnbrel (etanercept) — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization and submit documentation of prior therapies and positive clinical response to support a 12-month approval.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthstypical authorization duration for chronic indications

1 monthSJS/TEN (ICI toxicity)

Ages 2+min age — pJIA & juvenile indications

Ages 4+min age — plaque psoriasis

TB test ≤6mrequired TB screening window

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Psoriatic arthritis (PsA) — Initial therapy

Authorization of 12 months may be granted for members 2 years of age or older for treatment of active psoriatic arthritis when either of the following criteria is met:

ANY of the following

Member has mild to moderate disease and has had an inadequate response to methotrexate, leflunomide, or another conventional synthetic drug (e.g., sulfasalazine) administered at an adequate dose and duration.
Member has mild to moderate disease and has an intolerance or contraindication to methotrexate or leflunomide (see Appendix A), or another conventional synthetic drug (e.g., sulfasalazine).
Member has mild to moderate disease and has enthesitis or predominantly axial disease.
Member has severe disease.

Ankylosing spondylitis (AS) / non-radiographic axial spondyloarthritis (nr-axSpA) — Initial therapy

Authorization of 12 months may be granted for adult members for treatment of active ankylosing spondylitis or active non-radiographic axial spondyloarthritis when any of the following criteria is met:

ANY of the following

Member has experienced an inadequate response to at least two non-steroidal anti-inflammatory drugs (NSAIDs).
Member has an intolerance or contraindication to two or more NSAIDs.

Plaque psoriasis (PsO) — Initial therapy

Authorization of 12 months may be granted for treatment of moderate to severe plaque psoriasis in members 4 years of age or older when any of the following criteria is met:

ANY of the following

Crucial body areas (e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas) are affected.
At least 10% of the body surface area (BSA) is affected.
At least 3% of body surface area (BSA) is affected and the member has had an inadequate response or intolerance to either phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with methotrexate, cyclosporine, or acitretin.
At least 3% of BSA is affected and the member has a clinical reason to avoid pharmacologic treatment with methotrexate, cyclosporine, and acitretin (see Appendix C).

Reactive arthritis — Initial therapy

Authorization of 12 months may be granted for treatment of reactive arthritis when any of the following criteria is met:

ANY of the following

Member has experienced an inadequate response to at least a 3-month trial of sulfasalazine (i.e., titrated to 1000 mg twice daily) despite adequate dosing or maximally tolerated dose.
Member has experienced an inadequate response to at least a 3-month trial of methotrexate (i.e., titrated to at least 15 mg/week) despite adequate dosing or maximally tolerated dose.
Member has an intolerance or contraindication to methotrexate and sulfasalazine (e.g., porphyria, intestinal or urinary obstruction).

Hidradenitis suppurativa (severe, refractory) — Initial therapy

Authorization of 12 months may be granted for treatment of severe, refractory hidradenitis suppurativa when either of the following is met:

ANY of the following

Member has experienced an inadequate response to an oral antibiotic for at least 90 days.
Member has an intolerance or contraindication to oral antibiotics.

Graft versus host disease — Initial therapy

Authorization of 12 months may be granted for treatment of graft versus host disease when either of the following criteria is met:

ANY of the following

Member has experienced an inadequate response to systemic corticosteroids.
Member has an intolerance or contraindication to corticosteroids.

Immune checkpoint inhibitor toxicity — Initial therapy

Authorization of 1 month may be granted for treatment of immune checkpoint inhibitor toxicity when the member has Stevens-Johnson syndrome or toxic epidermal necrolysis. Authorization of 12 months may be granted when the member has severe immunotherapy-related inflammatory arthritis and has experienced an inadequate response, intolerance, or contraindication to corticosteroids.

ANY of the following

Stevens-Johnson syndrome or toxic epidermal necrolysis (authorization of 1 month).
Severe immunotherapy-related inflammatory arthritis with inadequate response, intolerance, or contraindication to corticosteroids (authorization of 12 months).

Continuation criteria (all indications)

Authorization of 12 months may be granted for continuation of therapy for members (including new members) who are using the requested medication for the indications below and who achieve or maintain a positive clinical response. All members requesting continuation must meet all initial authorization criteria.

Psoriatic arthritis — continuation

Authorization of 12 months may be granted for members 2 years of age or older who achieve or maintain a positive clinical response as evidenced by improvement from baseline in any of the following: number of swollen joints, number of tender joints, dactylitis, enthesitis, axial disease, skin and/or nail involvement.

Ankylosing spondylitis and nr-axSpA — continuation

Authorization of 12 months may be granted for adult members who achieve or maintain a positive clinical response as evidenced by improvement from baseline in any of the following: functional status, total spinal pain, inflammation (e.g., morning stiffness).

Reactive arthritis — continuation

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Requirement and Duration

Prior authorization is required for the requested biologic/targeted synthetic therapies. Authorizations are typically for 12 months when continuation criteria are met; initial approvals may require documentation of prior therapy trials or biomarker testing as specified in clinical criteria.

Prior authorization required for biologic/targeted synthetic drugs
Typical authorization duration: 12 months when continuation criteria met

Step Therapy

Step Therapy / Prior Trial Requirements

Step therapy and prior trial requirements vary by indication. In many adult indications (e.g., RA, PsA, AS/nr-axSpA) the member must have had an inadequate response to or intolerance/contraindication to specified conventional therapies (e.g., methotrexate, leflunomide, sulfasalazine, NSAIDs) or prior biologic/targeted synthetic therapy before approval is granted. For JIA and pediatric indications, trials of methotrexate or other conventional synthetic DMARDs or NSAIDs/intra-articular glucocorticoids are required unless contraindicated. Document prior medication trials, duration, dosing, and clinical response; if therapy is not advisable, provide clinical rationale (see Appendices A and C for example contraindications/reasons to avoid).

RA: inadequate response to ≥3 months methotrexate at adequate dosing (≥15 mg/week) or intolerance/contraindication
PsA: inadequate response to methotrexate/leflunomide or intolerance/contraindication
AS/nr-axSpA: inadequate response to ≥2 NSAIDs or intolerance/contraindication
JIA: inadequate response to methotrexate or another conventional synthetic DMARD or NSAID/intra-articular steroid trial

Billing Rule

Dosage limits and optimization

Approvals may be subject to dosing limits consistent with FDA labeling, compendia, and evidence-based guidelines. Use dose optimization with 50 mg product formulations when possible. Exceptions permitting higher quantities of 25 mg vials are allowed for documented latex allergy or when following FDA weight-based dosing.

Dosing limits follow FDA-approved labeling and accepted compendia
Prefer 50 mg formulations for dose optimization when clinically appropriate
Allow exceptions for higher 25 mg vial quantities for latex allergy or FDA weight‑based dosing

Documentation Required

Clinical response documentation

For continuation authorizations, provide chart notes or medical record documentation demonstrating a positive clinical response or maintenance of low disease activity compared with baseline. Acceptable evidence includes reductions in swollen/tender joint counts, improvement in number of joints with active arthritis or limitation of movement, reduced BSA or psoriasis signs, decreases in abscess/inflammatory nodule counts for hidradenitis suppurativa, improved functional status, reduced spinal pain/morning stiffness, or validated disease severity/quality-of-life measures.

Document objective measures of improvement from baseline (e.g., joint counts, BSA, lesion counts, pain, function)
For RA/JIA/PsA/AS/nr-axSpA/PsO/HS provide specific signs of clinical response as applicable

Denial Risk

TB-related denial risk and Concomitant biologic use

All members must have documented tuberculosis (TB) screening prior to initiating therapy if biologic/targeted synthetic–naïve: a negative TB test (PPD, IGRA, or chest x‑ray) within 6 months of starting therapy. If TB screening is positive, further evaluation to exclude active TB is required and latent TB must be treated prior to initiation. Failure to provide required TB screening/documentation may result in denial of the request. Additionally, the requested medication cannot be used concomitantly with any other biologic or targeted synthetic agent; requests that propose overlapping biologic/targeted synthetic use will be denied unless clear justification and rationale are documented and consistent with policy.

Document negative TB test (PPD, IGRA, or chest x‑ray) within 6 months for biologic/targeted synthetic–naïve members
If TB test positive: confirm no active disease and treat latent TB before starting therapy
Concomitant use of multiple biologic or targeted synthetic agents is not allowed and may lead to denial

Definitions and Clinical Response Metrics

Positive clinical response — Rheumatoid arthritis (RA)

Definition (RA) — thresholdDisease activity improvement of at least 20% from baseline in tender joint count, swollen joint count, pain, or disability

Documentation neededChart notes or medical record documentation showing baseline measures and ≥20% improvement

ApplicabilitySupports 12‑month continuation authorization for adult members using the requested medication for RA

Positive clinical response — Juvenile idiopathic arthritis (JIA) and Psoriatic arthritis (PsA)

Definition (JIA/PsA)Improvement from baseline in joint counts, functional ability, or condition‑specific signs such as dactylitis, enthesitis, or axial disease

JIA examplesImprovement in number of joints with active arthritis, limitation of movement, or functional ability

PsA examplesImprovement in swollen/tender joints, dactylitis, enthesitis, axial disease, or skin/nail involvement

Articular juvenile idiopathic arthritis — continuation criteria

Articular JIA continuation measureMember is ≥2 years old and achieves or maintains a positive clinical response evidenced by improvement in number of joints with active arthritis, number of joints with limitation of movement, or functional ability from baseline

Age requirementMember must be 2 years of age or older

Authorization periodAuthorization of 12 months may be granted for members meeting continuation criteria

Plaque psoriasis — continuation criteria

Plaque psoriasis continuation measureMember is ≥4 years old and achieves or maintains a positive clinical response evidenced by reduction in body surface area (BSA) affected or improvement in signs/symptoms from baseline (e.g., itching, redness, flaking, scaling, burning, cracking, pain)

Age requirementMember must be 4 years of age or older

Authorization periodAuthorization of 12 months may be granted for members meeting continuation criteria

OpenPayer

Enbrel (etanercept) — Coverage Criteria

Coverage Criteria for Enbrel (etanercept)

Testing and Screening Requirements

Provider Actions, Prior Authorization, and Documentation

Background on Enbrel (etanercept)

Definitions and Clinical Response Metrics